Mechanistically, LATS1/2‐null tumour cells secrete nucleic acid‐rich extracellular vesicles, which induce a type I interferon response via the Toll‐like receptor MYD88/TRIF pathway, thus improving tumour immunogenicity 80. This evidence concerns the gene LATS1 and neoplasm.